IRON vs PTGX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
PTGX is the larger of the two ($8.00B market cap): the incumbent the market prices for continued execution (351.94x forward earnings, beta 1.22). IRON is the smaller challenger ($3.40B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, IRON fits (beta 2.01). If you want the steadier ride, PTGX fits (beta 1.22).
IRON vs PTGX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IRON | PTGX | What it tells you |
|---|---|---|---|
| Market cap | $3.40B | $8.00B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -12.24 | 351.94 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 2.01 | 1.22 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 58% of range | 54% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 4.77 | 7.36 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how IRON and PTGX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IRON and PTGX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IRON and PTGX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Disc Medicine (IRON) do?
Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its programs aim to modify the biological pathways behind red blood cell formation and function, principally heme biosynthesis and iron homeostasis. The lead pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), selcodebart (DISC-0974, an anti-hemojuvelin antibody) for anemia of myelofibrosis, and DISC-3405 (an anti-TMPRSS6 antibody) being studied in conditions like polycythemia vera and sickle cell disease. The current company was formed when Disc Medicine reverse-merged into Gemini Therapeutics in December 2022 and began trading under the ticker IRON.
What does Protagonist Therapeutics (PTGX) do?
Protagonist Therapeutics is a Newark, California biotech that discovers oral and injectable peptide-based drugs and develops them mostly through large-pharma partners. Its two lead assets define the company: icotrokinra, an oral IL-23 receptor antagonist licensed to Johnson & Johnson and launched in the U.S. in March 2026 (branded ICOTYDE) for moderate-to-severe plaque psoriasis, and rusfertide, a once-weekly injectable hepcidin mimetic licensed to Takeda that the FDA approved in August 2026 as MIMRYLO for erythrocytosis in adults with polycythemia vera. ICOTYDE has since also been approved in China, Japan and the EU. Behind those, the pipeline includes an oral IL-17 antagonist (PN-881), an oral hepcidin functional mimetic (PN-8047), and obesity dual and triple agonists such as PN-477, most still in early stages.
IRON vs PTGX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- IRON drivers: Bitopertin: APOLLO succeeded, approval is next; Selcodebart (DISC-0974) in anemia of myelofibrosis.
- PTGX drivers: Icotrokinra (ICOTYDE) launch with J&J; MIMRYLO (rusfertide) launch with Takeda.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Disc Medicine is a clinical-stage company with no product revenue, so it is not profitable and its value rests on programs that can still fail. For PTGX, as a partner-dependent biotech, Protagonist has limited control over commercial execution: ICOTYDE's uptake and MIMRYLO's launch sit largely with J&J and Takeda, and Protagonist no longer controls MIMRYLO's pricing, market access or commercial investment.
IRON or PTGX: which should you pick?
If the story you believe is IRON's (Bitopertin: APOLLO succeeded, approval is next), IRON is the more direct way to own it; if it is PTGX's (Icotrokinra (ICOTYDE) launch with J&J), PTGX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IRON and PTGX guides.
IRON vs PTGX: the full fundamentals
IRON. As a clinical-stage biotech, Disc has no product sales, so traditional metrics like P/E do not apply and the company is valued on its pipeline's expected value and its cash. Its September cash plus the October raise comes to roughly $1.2 billion, about a third of its market value near $3.4 billion, so a big share of the price is the balance sheet plus the value the market assigns to a bitopertin approval and to selcodebart and DISC-3405. The mean analyst target among 13 tracked by Yahoo was about $128 in November 2026, with Guggenheim starting coverage at $132, and the FDA resubmission and mid-2027 decision are the next major events.
PTGX. As of November 2026, revenue is dominated by milestone and collaboration payments, including Takeda's $200 million initial opt-out payment in Q2 and the further $200 million opt-out fee plus $75 million MIMRYLO approval milestone recognized mostly in Q3. That lifted trailing twelve-month net income to about $342 million and the trailing P/E to a modest-looking 26x, but consensus sees 2027 revenue near $236 million and EPS of only about $0.35, which is why the forward P/E of about 350x says little either. The valuation is really a bet on the royalty streams from ICOTYDE and MIMRYLO; the average analyst target is about $182 (14 analysts), and UBS initiated at Buy with a $184 target in October 2026.
Headline figures (approximate, November 2026): IRON shows revenue (ttm) ~$0 (pre-revenue, clinical stage); ~$44 million expected for 2027, net loss (ttm) ~$243 million (EPS ~-$6.34), q3 2026 net loss ~$59.5 million; EPS -$1.53 vs -$1.71 estimate, cash and investments (sept. 30, 2026) ~$683 million, plus ~$486 million net raised in October; ~$61 million debt; PTGX shows market cap ~$8.0B, share price ~$121.85 (up ~40% YTD, ~45% over one year), revenue (ttm) ~$552M, q3 2026 revenue ~$274.4M (~$266.6M from the Takeda opt-out fee and MIMRYLO milestone).
The bottom line: IRON vs PTGX
IRON and PTGX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined IRON and PTGX exposure against your real portfolio. It is not an investment adviser.
Wondering how IRON or PTGX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Disc Medicine
Ask Walnut's AI anything about IRON and see how it fits what you own.
FAQ
What is the difference between IRON and PTGX?
+
Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Protagonist Therapeutics is a Newark, California biotech that discovers oral and injectable peptide-based drugs and develops them mostly through large-pharma partners. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IRON or PTGX the better stock?
+
Neither is universally better. PTGX is the larger incumbent; IRON is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IRON or PTGX?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IRON and PTGX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IRON vs PTGX?
+
IRON: Disc Medicine is a clinical-stage company with no product revenue, so it is not profitable and its value rests on programs that can still fail. APOLLO's success lowers but does not remove regulatory risk: the February 2026 complete response letter for bitopertin is a reminder that the FDA can ask for more, and a decision is not expected until around mid-2027. Selcodebart and DISC-3405 are still in Phase 2 or earlier, and disappointing data at ASH in December 2026 or at later readouts could weigh on the stock. Dizziness affected half of APOLLO patients, which could matter for labeling and uptake. The shares traded at $74.78 on November 20, 2026, still well below their 52-week high of $99.50. The company burns roughly $60 million a quarter, and the October 2026 offering of about $486 million net shows it will sell stock when needed, which dilutes existing shareholders. Even successful drugs face commercial risk in small rare-disease markets, competition from established therapies, manufacturing and reimbursement hurdles, and the concentration risk of a pipeline built around a few key programs. The stock is highly volatile and pays no dividend. PTGX: As a partner-dependent biotech, Protagonist has limited control over commercial execution: ICOTYDE's uptake and MIMRYLO's launch sit largely with J&J and Takeda, and Protagonist no longer controls MIMRYLO's pricing, market access or commercial investment. Slow psoriasis or polycythemia vera launch traction, weak payer access, or disappointing later-stage data in psoriatic arthritis or inflammatory bowel disease could remove large chunks of the royalty value the stock currently prices in. Much of 2026's revenue is lumpy, one-time milestone and opt-out income, so analysts expect revenue to drop to about $236 million and EPS to about $0.35 in 2027, with a small loss expected in Q4 2026. The early pipeline, including obesity agonists, is unproven and competes against far larger, better-funded programs. An insider sold about $18.2 million of shares in September 2026, per an SEC filing. Valuation near an $8.0 billion market cap, roughly 14x trailing revenue and about 350x 2027 consensus earnings, already embeds substantial future success, and the shares are about 24% below their 52-week high of $160.81 after falling about 12% in the month to November 20, 2026, a reminder of how sharply they can move.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IRON or PTGX; figures are approximate and dated (as of November 2026). Verify current data before investing.